• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

登革病毒1型和2型的包膜糖蛋白结构域III可抑制病毒进入。

The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry.

作者信息

Chin J F L, Chu J J H, Ng M L

机构信息

Flavivirology Laboratory, Department of Microbiology, 5 Science Drive 2, National University of Singapore, Singapore 117597, Singapore.

出版信息

Microbes Infect. 2007 Jan;9(1):1-6. doi: 10.1016/j.micinf.2006.09.009. Epub 2006 Dec 6.

DOI:10.1016/j.micinf.2006.09.009
PMID:17196419
Abstract

Dengue virus (DV) is a flavivirus and its urban transmission is maintained largely by its mosquito vectors and vertebrate host, often human. In this study, investigation was carried out on the involvement of domain III of the envelope (E) glycosylated protein of dengue virus serotypes 1 and 2 (DV-1 and DV-2 DIII) in binding to host cell surfaces, thus mediating virus entry. Domain III protein of flavivirus can also serve as an attractive target in inhibiting virus entry. The respective DV DIII proteins were expressed as soluble recombinant fusion proteins before purification through enzymatic cleavage and affinity purification. The purified recombinant DV-1 and DV-2 DIII proteins both demonstrated the ability to inhibit the entry of DV-1 and DV-2 into HepG2 cells and C6/36 mosquito cells. As such, the DV DIII protein is indeed important for the interaction with cellular receptors in both human and mosquito cells. In addition, this protein induced antibodies that completely neutralized homologous dengue serotypes although not with the same efficiency among the heterologous serotypes. This observation may be of importance when formulating a generic vaccine that is effective against all dengue virus serotypes.

摘要

登革病毒(DV)是一种黄病毒,其在城市中的传播主要由蚊媒和脊椎动物宿主(通常是人类)维持。在本研究中,对登革病毒1型和2型(DV - 1和DV - 2)包膜(E)糖蛋白的结构域III(DV - 1和DV - 2 DIII)在与宿主细胞表面结合从而介导病毒进入过程中的作用进行了研究。黄病毒的结构域III蛋白也可作为抑制病毒进入的一个有吸引力的靶点。通过酶切和亲和纯化对各自的DV DIII蛋白进行纯化前,先将其表达为可溶性重组融合蛋白。纯化后的重组DV - 1和DV - 2 DIII蛋白均显示出能够抑制DV - 1和DV - 2进入HepG2细胞和C6/36蚊细胞。因此,DV DIII蛋白对于在人类和蚊细胞中与细胞受体的相互作用确实很重要。此外,该蛋白诱导产生的抗体能够完全中和同源登革血清型,尽管在异源血清型之间的中和效率不同。在制定针对所有登革病毒血清型均有效的通用疫苗时,这一观察结果可能具有重要意义。

相似文献

1
The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry.登革病毒1型和2型的包膜糖蛋白结构域III可抑制病毒进入。
Microbes Infect. 2007 Jan;9(1):1-6. doi: 10.1016/j.micinf.2006.09.009. Epub 2006 Dec 6.
2
An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells.登革2型病毒包膜蛋白结构域III的一个外部环区参与了与蚊子而非哺乳动物细胞的血清型特异性结合。
J Virol. 2004 Jan;78(1):378-88. doi: 10.1128/jvi.78.1.378-388.2004.
3
Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.利用包膜糖蛋白的重组结构域III抑制西尼罗河病毒进入。
J Gen Virol. 2005 Feb;86(Pt 2):405-412. doi: 10.1099/vir.0.80411-0.
4
[Recombinant envelope glycoprotein domain III of dengue virus inhibit virus infection].[登革病毒重组包膜糖蛋白结构域III抑制病毒感染]
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Jun;22(3):177-9.
5
Rapid purification of recombinant dengue and West Nile virus envelope Domain III proteins by metal affinity membrane chromatography.通过金属亲和膜色谱法快速纯化重组登革热病毒和西尼罗河病毒包膜结构域III蛋白
Protein Expr Purif. 2010 Nov;74(1):129-37. doi: 10.1016/j.pep.2010.06.015. Epub 2010 Jul 1.
6
Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly.登革病毒包膜蛋白 DI/DIII 连接区突变可损害病毒粒子组装。
J Virol. 2012 Jul;86(13):7072-83. doi: 10.1128/JVI.00224-12. Epub 2012 Apr 24.
7
Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.一种新型DNA合成连接体四价登革热疫苗的研发,该疫苗可引发针对四种血清型的免疫反应。
Vaccine. 2009 Oct 30;27(46):6444-53. doi: 10.1016/j.vaccine.2009.06.061. Epub 2009 Jul 4.
8
Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells.登革病毒包膜蛋白结构域III与中国仓鼠卵巢细胞推定受体之间相互作用的表征
Virus Res. 2008 Nov;137(2):225-34. doi: 10.1016/j.virusres.2008.07.022. Epub 2008 Sep 21.
9
Does Japanese encephalitis virus share the same cellular receptor with other mosquito-borne flaviviruses on the C6/36 mosquito cells?日本脑炎病毒与其他蚊媒黄病毒在C6/36蚊细胞上是否共享相同的细胞受体?
Virol J. 2007 Sep 6;4:83. doi: 10.1186/1743-422X-4-83.
10
Dengue virus type 2 envelope protein displayed as recombinant phage attachment protein reveals potential cell binding sites.作为重组噬菌体附着蛋白展示的登革2型病毒包膜蛋白揭示了潜在的细胞结合位点。
Protein Eng Des Sel. 2008 Oct;21(10):605-11. doi: 10.1093/protein/gzn041. Epub 2008 Jul 30.

引用本文的文献

1
Identification of Rhododendron mariae extraction as a new attachment inhibitor against dengue virus by targeting the envelope protein domain III.通过靶向包膜蛋白结构域III鉴定杜鹃提取物作为一种新型登革病毒附着抑制剂
Front Immunol. 2025 Aug 13;16:1663878. doi: 10.3389/fimmu.2025.1663878. eCollection 2025.
2
Development of tobacco chloroplast vector with novel insertion sites for dengue virus (DENV) antigens.用于登革病毒(DENV)抗原的具有新插入位点的烟草叶绿体载体的开发。
Protoplasma. 2025 Jul 17. doi: 10.1007/s00709-025-02087-5.
3
THE REPLICATION EFFICIENCY OF DENGUE VIRUS SEROTYPE 1 ISOLATED FROM PATIENTS WITH DENGUE FEVER IN HUMAN HEPATOCYTE CELL LINES.
从登革热患者中分离出的1型登革病毒在人肝细胞系中的复制效率
Afr J Infect Dis. 2025 Apr 7;19(2):33-42. doi: 10.21010/Ajidv19i2.4. eCollection 2025.
4
The Low-Density Lipoprotein Receptor-Related Protein-1 Is Essential for Dengue Virus Infection.低密度脂蛋白受体相关蛋白1对登革病毒感染至关重要。
Viruses. 2024 Oct 30;16(11):1692. doi: 10.3390/v16111692.
5
In silico fragment-based design and pharmacophore modelling of therapeutics against dengue virus envelope protein.基于计算机模拟的登革病毒包膜蛋白治疗药物的片段设计与药效团建模
In Silico Pharmacol. 2024 Sep 20;12(2):87. doi: 10.1007/s40203-024-00262-9. eCollection 2024.
6
Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV Serotypes.针对所有四种登革病毒血清型的新型空间优化基于病毒样颗粒的疫苗的临床前评估。
Vaccines (Basel). 2024 Aug 1;12(8):874. doi: 10.3390/vaccines12080874.
7
Preexisting inter-serotype immunity drives antigenic evolution of dengue virus serotype 2.预先存在的血清型间免疫驱动登革病毒2型的抗原进化。
Virology. 2024 Feb;590:109951. doi: 10.1016/j.virol.2023.109951. Epub 2023 Dec 8.
8
Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections.新兴虫媒病毒感染治疗性单克隆抗体的研发。
Viruses. 2023 Oct 30;15(11):2177. doi: 10.3390/v15112177.
9
Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.登革病毒中和抗体:目标、交叉反应性和抗体依赖性增强的综述。
Front Immunol. 2023 Jun 2;14:1200195. doi: 10.3389/fimmu.2023.1200195. eCollection 2023.
10
Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins.生物信息学预测的登革热包膜和前膜蛋白线性 B 细胞表位的天然免疫原性。
BMC Immunol. 2021 Nov 3;22(1):71. doi: 10.1186/s12865-021-00462-4.